Anti-inflammatory diabetes therapy
Anti-inflammatory diabetes therapy has been studied in 1 paper since 2021: 1 observational study in people. The newest paper, Nov 24, 2021: “Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET”.
1 paper studies it1 findingUpdated
See all 1 papers on anti-inflammatory diabetes therapy
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“In a large COPD cohort, anti-inflammatory diabetes therapy, including metformin, was associated with a lower prevalence of osteoporosis, especially in patients with higher symptoms and exacerbations.”
- 1 lab in 1 country
- Funders: AstraZeneca and 7 more
- 1 of 1 finding with company ties
- Humans1
What is anti-inflammatory diabetes therapy linked with?
1Studies link anti-inflammatory diabetes therapy with 1 measure, most often osteoporosis (1 study).
Osteoporosis
downin humans1
1 study
Osteoporosis
downin humans1
Anti-inflammatory diabetes therapy is associated with osteoporosis in humans (COPD patients; driven by GOLD D patients) (p = 0.009).
“In a large COPD cohort, anti-inflammatory diabetes therapy, including metformin, was associated with a lower prevalence of osteoporosis, especially in patients with higher symptoms and exacerbations.”
HumansCOPD patients; driven by GOLD D patientsn = 2,222
International journal of chronic obstructive pulmonary disease